Eagle Health Investments LP Acquires Shares of 131,344 Dianthus Therapeutics, Inc. $DNTH

Eagle Health Investments LP bought a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 131,344 shares of the company’s stock, valued at approximately $12,803,000. Dianthus Therapeutics accounts for about 2.1% of Eagle Health Investments LP’s holdings, making the stock its 20th largest position.

A number of other hedge funds have also modified their holdings of the business. BlackRock Inc. purchased a new position in shares of Dianthus Therapeutics in the second quarter worth about $401,990,000. Deutsche Bank AG purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at about $6,800,000. TimesSquare Capital Management LLC acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at about $16,216,000. Persistent Asset Partners Ltd acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at about $543,000. Finally, Global Retirement Partners LLC purchased a new position in Dianthus Therapeutics in the 2nd quarter worth approximately $93,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

DNTH has been the subject of a number of analyst reports. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush boosted their price target on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $124.27.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $113.70 on Thursday. The firm has a market capitalization of $6.22 billion, a price-to-earnings ratio of -27.40 and a beta of 1.22. Dianthus Therapeutics, Inc. has a fifty-two week low of $22.06 and a fifty-two week high of $117.88. The stock has a 50 day moving average of $99.51 and a 200 day moving average of $84.41.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Insider Activity

In related news, SVP Adam M. Veness sold 16,167 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $110.38, for a total value of $1,784,513.46. Following the sale, the senior vice president directly owned 3,833 shares in the company, valued at approximately $423,086.54. The trade was a 80.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the transaction, the executive vice president directly owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 287,084 shares of company stock worth $29,615,923. 3.02% of the stock is currently owned by corporate insiders.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.